(Total Views: 455)
Posted On: 09/16/2020 7:56:19 PM
Post# of 154896
Little gem of management thinking with regards to dealing with BP on the last question in the Q&A:
Either they pay a shit ton of money to buy leronlimab/Cytodyn outright or Cytodyn moves forward on their own. No separate licenses based on use. Impossible to price by indication since its already been priced for HIV.
Either they pay a shit ton of money to buy leronlimab/Cytodyn outright or Cytodyn moves forward on their own. No separate licenses based on use. Impossible to price by indication since its already been priced for HIV.
(0)
(0)
